

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

HLA specificity for assessment		DR1403 Not Assessed 17.8%		DR1404 Not Assessed 16.4%		DR7 Present 95.9%		DR8 Present 94.5%		DR9 Present 91.8%		DR10 Absent 2.7%		DR51 Absent 2.7%		DR52 Present 95.9%		DR53 Absent 1.4%						
Consensus % reported	DR14 Present 94.5%	tech	MFI	tech	MFI	tech	MFI	tech	MFI	tech	MFI	tech	MFI	tech	MFI	tech	MFI	tech	MFI					
Lab no.	spec			spec		spec		spec		spec		spec		spec		spec		spec						
11	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
12	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
14	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
15	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
19	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
20	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
23	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
24	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
25	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
26	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
28	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
34	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
35	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
38	DR14	L	> 5000	DR1403	L	> 5000	DR1404	L	> 5000	DR7	L	> 5000	DR8	L	> 5000		DR52	L	> 5000					
39	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
41	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
42	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
45	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
48	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
51	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
54	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
58	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
62	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
100	DR14	L	> 5000	DR1403	L	> 5000	DR1404	L	> 5000	DR7	L	> 5000	DR8	L	> 5000		DR52	L	> 5000					
112	DR14	L	> 5000	DR1403	L	> 5000	DR1404	L	> 5000	DR7	L	> 5000	DR8	L	2000-5000		DR52	L	> 5000					
114	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
116	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
117	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
119	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
120	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
133	DR14	L	> 5000	DR1403	L	> 5000	DR1404	L	> 5000	DR7	L	> 5000	DR8	L	2000-5000		DR52	L	> 5000					
136	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
142	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
143	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
145	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
149	DR14	L	> 5000	DR1403	L	> 5000	DR1404	L	> 5000	DR7	L	> 5000	DR8	L	2000-5000		DR52	L	> 5000					
157	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
160	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
162	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
165	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
169	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	< 2000		DR52	L	> 5000						
181	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
185	DR14	L	> 5000	DR1403	L	> 5000	DR1404	L	> 5000	DR7	L	> 5000	DR8	L	> 5000		DR52	L	> 5000					
194	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
195	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
197	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000	DR51	L	> 5000	DR52	L	> 5000	DR53	L	> 5000	
206	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
212	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000	DR10	L	> 5000	DR52	L	> 5000				
214	DR14	L	< 2000	DR1403	L	< 2000	DR1404	L	< 2000	DR7	L	< 2000	DR8	L	< 2000		DR52	L	< 2000					
216	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
218	DR14	L	> 5000	DR1403	L	> 5000	DR1404	L	> 5000	DR7	L	> 5000	DR8	L	> 5000	DR9	F	> 5000	DR52	L	> 5000			
222	DR14	F	> 5000			DR7	F	> 5000	DR8	F	> 5000	DR9	F	> 5000	DR10	F	> 5000	DR52	F	> 5000				
227	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
229	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
230	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
232	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
242	DR14	L	> 5000	DR1403	L	> 5000	DR1404	L	> 5000	DR7	L	> 5000	DR8	L	> 5000		DR52	L	> 5000					
252	DR14	L	> 5000	DR1403	L	> 5000	DR1404	L	> 5000	DR7	L	> 5000	DR8	L	2000-5000		DR52	L	> 5000					
267	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
273	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
277	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
284	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
292	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
293	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	2000-5000		DR52	L	> 5000						
294	DR14	L	> 5000	DR1403	L	> 5000	DR1404	L	> 5000	DR7	L	> 5000	DR8	L	2000-5000		DR52	L	> 5000					
302	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
303	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000	DR51	L	2000-5000	DR52	L	> 5000				
309	DR14	L	> 5000	DR1403	L	> 5000				DR7	L	> 5000	DR8	L	2000-5000		DR52	L	> 5000					
351	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						
361	DR14	L	> 5000	DR1403	L	> 5000	DR1404	L	> 5000	DR7	L	> 5000	DR8	L	2000-5000		DR52	L	> 5000					
392	DR14	L	> 5000			DR7	L	> 5000	DR8	L	> 5000	DR9	L	> 5000		DR52	L	> 5000						

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

HLA specificity for assessment																		
Lab no.	DQ5 Absent 1.4%		DQ6 Not Assessed 27.4%			DQ2 Present 93.2%			DQ7 Not Assessed 31.5%			DQ9 Absent 2.7%			DQ4 Not Assessed 27.4%			
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9																		
11																		
12																		
14																		
15																		
19																		
20																		
23																		
24																		
25																		
26																		
28																		
34																		
35																		
38																		
39																		
41																		
42																		
45																		
48																		
51																		
54																		
58																		
62																		
100																		
112																		
114																		
116																		
117																		
119																		
120																		
133																		
136																		
142																		
143																		
145																		
149																		
157																		
160																		
162																		
165																		
169																		
181																		
185																		
194																		
195																		
197																		
206																		
212																		
214																		
216																		
218																		
222																		
227																		
229																		
230																		
232																		
242																		
252																		
267																		
268																		
273																		
277																		
284																		
292																		
293																		
294																		
302																		
303																		
309																		
351																		
361																		
392																		

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

1	< 2000	20	< 2000	68	< 2000	23	< 2000	2	< 2000	20	< 2000
73	1	73	18	73	1	73	0	73	0	73	0
	2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
	0		0		8		1		1		1
	> 5000		> 5000		> 5000		> 5000		> 5000		> 5000
	0		2		58		22		0		18

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 3 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	01:01			02:01			03:01			04:01			04:02			05:01			11:01			13:01			14:01			18:01		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
11																														
12																														
14																														
15																														
19																														
20																														
23																														
24																														
25																														
26																														
28																														
34																														
35																														
36																														
39																														
41																														
42																														
45																														
48																														
51																														
54																														
58																														
62																														
100	01:01	L	< 2000						04:01	L	< 2000			05:01	L	< 2000														
112																														
114																														
116																														
117																														
119																														
120																														
133																														
136																														
142																														
143																														
145																														
149																														
157																														
160																														
162																														
165																														
169																														
181																														
185																														
194																														
195																														
197																														
206																														
212	01:01	L	> 5000			03:01	L	> 5000	04:01	L	2000-5000	04:02	L	> 5000					13:01	L	> 5000									
214																														
216																														
218																														
222				02:01	F							04:02	F		05:01	F		11:01	F		13:01	F		14:01	F		18:01	F		
227																														
229																														
230																														
232																														
242																														
252																														
267									04:01	L	< 2000																			
268																														
273																														
277																														
284																														
292																														
293																														
294																														
302																														
303																														
309																														
351																														
361																														
392																														

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	< 2000		1 < 2000		1 < 2000		3 < 2000		2 < 2000		2 < 2000		1 < 2000		2 < 2000		1 < 2000		1 < 2000		1 < 2000	
Total Participants	73	1	73	0	73	0	73	2	73	0	73	1	73	0	73	0	73	0	73	0	73	0
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		0		0		0		1		0		0		0		0		0		0		0
		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000
		1		0		1		0		1		0		0		1		0		0		0

NEQ-120

Issue 3

UK NEQAS for H+I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 4 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H+I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	01:02 Not Assessed 5.5%			02:01 Absent 4.1%			03:01 Absent 4.1%			04:01 Not Assessed 72.6%			05:01 Not Assessed 58.9%			05:05 Not Assessed 61.6%			06:01 Not Assessed 72.6%			
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	
11																						
12																						
14																						
15																						
19																						
20	01:02	L	< 2000																			
23																						
24																						
25																						
26																						
28																						
34																						
35				02:01	L	2000-5000	03:01	L	2000-5000													
38																						
39																						
41																						
42																						
45																						
48																						
51																						
54																						
58																						
62																						
100	01:02	L	< 2000																			
112																						
114																						
116																						
117																						
119																						
120																						
133																						
136																						
142	01:02	L	< 2000																			
143																						
145																						
149																						
157																						
160																						
162																						
165																						
169																						
181																						
185																						
194																						
195																						
197																						
206																						
212																						
214																						
216																						
218																						
222																						
227																						
229																						
230																						
232	01:02	L	< 2000	02:01	L	> 5000	03:01	L	> 5000													
242																						
252																						
267																						
268																						
273																						
277																						
284																						
292																						
293																						
294																						
302																						
303																						
309																						
351				02:01	L	> 5000	03:01	L	> 5000													
361																						
362																						

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	4	< 2000	3	< 2000	3	< 2000	53	< 2000	43	< 2000	45	< 2000	53	< 2000
Total Participants	73	4	73	0	73	0	73	2	73	2	73	0	73	4
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		0		1		1		11		6		0		6
		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000
		0		2		2		39		34		45		42

NEQ-120

Issue 3

UK NEQAS for H+I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 5 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H+I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 31

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

DPA1* Antibodies - NOT ASSESSED			
Consensus	02:02	Absent	
% reported	1.4%		
Lab no.	spec	tech	MFI
9			
11			
12			
14			
15			
19			
20			
23			
24			
25			
26			
28			
34			
35			
38			
39			
41			
42			
45			
48			
51			
54			
58			
62			
100			
112			
114			
116			
117			
119			
120			
133			
136			
142			
143			
145			
149			
157			
160			
162			
165			
169			
181			
185			
194			
195			
197			
206			
212			
214			
216			
218			
222			
227			
229			
230			
232			
242			
252			
267	02:02	L	< 2000
268			
273			
277			
284			
292			
293			
294			
302			
303			
309			
351			
361			
392			

Technique : C = CDC; E = ELISA; F = Flow cytometry; L =

No. Reporting Spec	1	< 2000
Total Participants	73	1
		2000-5000
		0
		> 5000
		0

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 6 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 301/2018

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	Techniques used IgG	Sample Treatment IgG	High Background	Neg control serum batch	Allele Specific Antibodies IgG	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative
9	L	EDTA	No			LSAII	1500	9000	150								
11	I	EDTA	No	18		LS2A01	1000	3392	80	LSM12	2.5	5384	74				
12	L	EDTA	No	18		LS2A01	500	8537	76								
14	L	Heat Inactivation, EDTA	No	18	DQA1*05:03 >5000	LS2A01	1500	10523	51								
15	L	EDTA	No	18	DQA1*05:03	LS2A01	1000	10827	70								
19	L	None	No		DQA1*05:03	LS2A01	1000	7670	68								
20	C+L	EDTA	No		DQA1*05:03	LS2A01	1000	11750	66								
					DRB1*04:02												
					DQB1*04:02, 06:09												
23	L	EDTA	No	19	DQA1*05:03	LS2A01	1000	8032	22								
24	L	EDTA	No	18	DQB1*06:09	LS2A01	1000	10382	108	LSM12	4.5	9402	475	LS2PRA	1000	10608	48
					DRB1*04:02												
25	L	EDTA	No	19	DRB1*04:02	LS2A01	1000	8050	241	LSM12	6.1	12625	133	LSAII	1500	19600	71
					DQB1*04:02, 06:09												
					DQA1*04:01												
26	L	EDTA	No	19		LS2A01	1990	10852	73	LSM12	4.5	11900	94				
28	L	None	No		DRB1*04:02	LS2A01	500	6887	31								
					DQB1*06:03, 06:09												
34	L	EDTA	No	18	DQA1*05:03	LS2A01	1483/857	10234	36								
35	L	EDTA	No	19	DRB1*15:02	LS2A01	1000	9957	40								
38	L	EDTA	No	18	DQA1*05:03	LS2A01		9715	28	LSAII		16566	779				
39	L	EDTA	No	18	DQA1*05:03 >5000	LS2A01	820	7221	128								
41	L	EDTA	No	18		LS2A01	2000	6818	18								
42	L	EDTA	No	18	DRB1*04:02	LS2A01	500	9570	63								
					DQB1*06:09												
					DQA1*05:03												
45	L	EDTA, Adsorption	No		DQA1*05:03	LS2A01	1500	11000	40								
48	L	Heat Inactivator	No	19	DQA1*05:03												
51	L	EDTA	No			LS2A01	1800	8848	81								
54	L	EDTA	No	18	DQA1*05:03	LS2A01	1000	6886	98								
					DRB1*04:02												
					DQB1*06:09												
58	L	EDTA	No	18		LS2A01	1000	10096	53								
62	L	None	No	19		LS2A01	1500	11038	60	LSAII	750	15610	203				
100	F	None	No	3006101		LSAII	556	1718	172								
112	L	None	No	3005857	DRB1*15:01, 16:01	LSAII	500	16219	140								
114	L	EDTA	No		DRB1*01:03, 04:02	LS2A01	1000	29	4904								
116	L	EDTA	No	18	DRB1*04:02	LS2A01	1000	6391	155	LSM12		6228	124				
					DQB1*06:09												
117	L	None	No	18	DQA1*05:03 >5000	LS2A01	500	7309	41								
119	I	EDTA	No		DQA1*05:03	LS2A01	>1000	6915	39	LSM12	>1.5	9415	29				
					DRB1*04:02												
					DQB1*06:09												
120	L	EDTA	No		DQA1*04:01	LS2A01	500	7581	26								
					DRB1*04:02												
					DQB1*06:09												
					DQA1*05:03												
133	L	Heat Inactivation	No	3005855	DRB1*03:01/02/03, 07:01, 08:01/02, 09:01, 11:01/03/04, 12:01/02, 13:01/03/05, 14:01/03/04, 15:01/02/03, 16:01	LSAII		16037	130								
					DRB3*01:01/02:02/03:01												
136	L	None	No		DQB1*02:01/02	LS2A01	1000	12292	79								
					DQA1*05:03												
					DQB1*06:09												
					DQA1*01:02												
142	L	EDTA	No			LS2A01	1000	9912	33								
143	L	None	No			LS2A01	1000	12368	448								
145	L	None	No	16	DQA1*05:03	LS2A01	1000	7172	23								
149	L	None	No			LSAII	1000	17583	405								
157	L	EDTA	No	18	DRB1*04:02	LS2A01	1000	6612.4	84.5								
160	L	Adsorption	No	17		LS2A01	1000	8154	31.7								
162	L	EDTA	No		DRB1*16:01	LS2A01	1000	9296	29	LSM12	3	7767	53				
					DQA1*05:03 >5000												
165	L	None	No			LS2A01	61	6818	111								
169	L	None	No			LS2A01	1000	1472	13								
181	L	None	No	18		LS2A01	500	7050	109								
					DQB1*03:01, 04:02												
185	L	EDTA	Yes		DQA1*04:01, 05:03, 05:05, 06:01	LSAII	2	20365	247								
194	L	EDTA	No		DRB1*04:02	LS2A01	1000	10170	51								
195	L	None	No		DQB1*06:09	LS2A01	1000	7370	36								
197	L	None	No														
206	L	EDTA	No		DQA1*05:03	LS2A01	1000	11873	23								
212	L	None	No			LM2	100	19916	108								

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 7 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

Ref	Technique	Result	Comments	Antigen	Antibody	Value	Value	Value	Value	Value	Value	Value
214	L	None	Yes	DRB1*03:01/03:02/03:03/07:01/08:01/08:02/11:01/11:03/11:04/12:02/13:01/13:03/13:05/14:01/14:03/14:04	LSAII	750	1779	86	UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS			
216	L	None		DRB3*01:01/02:02/03:01	LM2	5000	16592	614				
218	L	None	No	DQB1*02:01, 02:02	LSAI&II	750	17416	153				
222	F	None		DRB1*03:01/03:02/03:03/07:01/08:01/08:02/09:01/11:01/11:03/11:04/12:01/12:02/13:01/13:03/13:05/14:01/14:03/14:04/15:XX								
227	L	Dilution, EDTA	No	DRB3*01:01/02:02/03:01								
229	L	None	No	DQA1*04:01/05:01/06:01								
230	L	None	No	DQB1*06:03, 06:09								
232	L	None	No	DRB1*04:02								
242	L	Adsorption	No	LM2	1000	>10000	155					
252	L	None	No	LS2A01	1200		6482	25				
267	L	EDTA	No	DRB1*03			20544	193				
268	C+L	EDTA	No	LM2	2		21696	240				
273	L	None	No	LSAII	700		13240	126				
277	L	EDTA	No	LS2A01	2000		10212	9	LS2PRA	2000	8649	68
284	L	EDTA	No	DRB1*04:02, 14:01, 14:54, 14:02	LS2A01	1500	9461	64				
292	L	EDTA	No	DQB1*06:09								
293	L	None	No	DQA1*05:03	LS2A01	500	6794	34				
294	L	None	No	DRB1*04:02								
302	L	None	No	DQA1*05:03	LS2A01	1000	8565	40.46				
303	L	EDTA, Heat Inactivation	No	DQB1*06:09								
309	L	None	No	LS2A01	500		9177	253	LSM12	2.5	10586	46
351	L	EDTA	No	LS2A01	500		6385	20.2				
361	L	None	No	DRB1*04:02	LSAII		15968					
392	L	None	No	DRB1*04:02	LS2A01	1000	7953	143				
	L	None	No	DQA1*05:03	LSAII	500	16500	122				
	L	EDTA	No	LS2A01	1500		8282	112				
	L	None	No	DRB1*15:01/02	LSAII	500	17893	134				

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/201:

DESPATCHED ON 17TH APRIL 2016

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	DR1 Not Assessed 20.5%			DR103 Absent 2.7%			DR15 Not Assessed 8.2%			DR16 Not Assessed 5.5%			DR17 Not Assessed 9.6%			DR18 Not Assessed 5.5%			DR4 Present 94.5%			DR11 Absent 1.4%			DR12 Absent 1.4%			DR13 Absent 2.7%			
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	
9																															
11																															
12																															
14																															
15																															
19																															
20																															
23																															
24																															
25																															
26																															
28	DR1	L	< 2000				DR15	L	< 2000																						
34																															
35																															
38																															
39																															
41																															
42	DR1	L	< 2000				DR15	L	< 2000				DR17	L	< 2000																
45																															
48																															
51	DR1	L	< 2000																												
54																															
58																															
62																															
100																															
112																															
114																															
116																															
117	DR1	L	< 2000				DR15	L	< 2000																						
119																															
120	DR1	L	< 2000																												
133																															
136	DR1	L	< 2000																												
142																															
143																															
145																															
149																															
157																															
160																															
162																															
165																															
169																															
181																															
185	DR1	L	< 2000																												
194																															
195																															
197	DR1	L	> 5000	DR103	L	> 5000			DR16	L	> 5000	DR17	L	> 5000	DR18	L	> 5000								DR13	L	> 5000				
206																															
212	DR1	L	2000-5000						DR16	L	< 2000	DR17	L	2000-5000	DR18	L	< 2000						DR12	L	2000-5000						
214																															
216																															
218																															
222	DR1	F		DR103	F		DR15	F		DR16	F		DR17	F		DR18	F								DR13	F					
227																															
229																															
230																															
232																															
242	DR1	L	< 2000																												
252																															
267									DR16	L	2000-5000														DR4	L	> 5000				
268																									DR4	L	> 5000				
273																									DR4	L	> 5000				
277	DR1	L	< 2000				DR15	L	< 2000				DR17	L	< 2000																
284	DR1	L	< 2000																												
292	DR1	L	< 2000				DR15	L	< 2000				DR17	L	< 2000																
293																															
294																															
302	DR1	L	2000-5000										DR17	L	2000-5000	DR18	L	< 2000					DR11	L	< 2000						
303																															
309																															
351																															
361																															
392																															

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	15 < 2000			2 < 2000			6 < 2000			4 < 2000			7 < 2000			4 < 2000			69 < 2000			1 < 2000			1 < 2000			2 < 2000		
Total Participants	73	11	0	73	0	0	73	5	0	73	1	2	73	2	0	73	0	0	73	0	1	73	0	1	73	0	0	73	0	0
		2000-5000	0		2000-5000	0		2000-5000	0		2000-5000	0		2000-5000	0		2000-5000	0		2000-5000	0		2000-5000	0		2000-5000	0		2000-5000	0
		> 5000	2		> 5000	0		> 5000	0		> 5000	1		> 5000	2		> 5000	0		> 5000	0		> 5000	0		> 5000	1		> 5000	0
			1			1			0			1			1			1			68			0	</					

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/201

DESPATCHED ON 17TH APRIL 2016

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

HLA specificity for assessment																														
Lab no.	DR14 Not Assessed 34.2%			DR7 Present 93.2%			DR8 Absent 1.4%			DR9 Present 76.7%			DR10 Not Assessed 5.5%			DR51 Not Assessed 27.4%			DR52 Absent 1.4%			DR53 Not Assessed 6.8%			DQ5 Not Assessed 69.9%			DQ6 Not Assessed 11.0%		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9				DR7	L	> 5000				DR9	L	2000-5000																		
11				DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
12				DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
14				DR7	L	> 5000																		DQ5	L	2000-5000				
15				DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
19				DR7	L	> 5000																		DQ5	L	2000-5000				
20				DR7	C+L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
23	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000	DQ6	L	< 2000	
24	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000					DR51	L	< 2000					DQ5	L	2000-5000				
25				DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
26				DR7	L	> 5000																		DQ5	L	2000-5000				
28	DR14	L	< 2000	DR7	L	> 5000				DR9	L	2000-5000					DR51	L	< 2000					DQ5	L	2000-5000				
34				DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
35				DR7	L	> 5000																		DQ5	L	2000-5000				
38				DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
39				DR7	L	> 5000																		DQ5	L	2000-5000				
41				DR7	L	> 5000																		DQ5	L	2000-5000				
42	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000					DR51	L	< 2000					DQ5	L	2000-5000	DQ6	L	< 2000	
45				DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
48				DR7	L	> 5000																		DQ5	L	2000-5000				
51				DR7	L	> 5000				DR9	L	2000-5000													DQ5	L	2000-5000			
54	DR14	L	< 2000	DR7	L	> 5000				DR9	L	2000-5000					DR51	L	< 2000					DQ5	L	> 5000	DQ6	L	< 2000	
58				DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
62				DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
100				DR7	L	> 5000				DR9	L	2000-5000																		
112				DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
114	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
116	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
117	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000					DR51	L	< 2000					DQ5	L	2000-5000				
119	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000					DR51	L	< 2000					DQ5	L	2000-5000				
120	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000					DR51	L	< 2000					DQ5	L	2000-5000	DQ6	L	< 2000	
133				DR7	L	> 5000				DR9	L	< 2000																		
136	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000					DR51	L	< 2000					DQ5	L	2000-5000	DQ6	L	< 2000	
142				DR7	L	> 5000				DR9	L	< 2000													DQ5	L	2000-5000			
143	DR14	L	2000-5000	DR7	L	> 5000				DR9	L	2000-5000												DQ5	L	> 5000				
145	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000					DR51	L	< 2000					DQ5	L	2000-5000				
149	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
157	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000					DR51	L	< 2000					DQ5	L	2000-5000				
160	DR14	L	< 2000	DR7	L	> 5000																		DQ5	L	< 2000				
162				DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
165				DR7	L	> 5000				DR9	L	< 2000												DQ5	L	< 2000				
169				DR7	L	> 5000																		DQ5	L	2000-5000				
181	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000					DR51	L	< 2000					DQ5	L	2000-5000				
185				DR7	L	> 5000				DR9	L	> 5000												DQ5	L	2000-5000				
194	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
195	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
197				DR7	L	> 5000				DR9	L	> 5000												DQ5	L	2000-5000				
206				DR7	L	> 5000				DR9	L	< 2000													DQ5	L	2000-5000			
212	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000												DQ5	L	2000-5000				
214				DR7	L	> 5000				DR9	L	2000-5000					DR10	L	< 2000					DR53	L	> 5000	DQ5	L	2000-5000	
216				DR7	L	> 5000																								
218				DR7	L	> 5000				DR9	L	< 2000																		
222				DR7	F	> 5000				DR9	F	< 2000					DR10	F						DR53	F					
227				DR7	L	> 5000				DR9	L	< 2000													DQ5	L	2000-5000			
229																														
230				DR7	L	> 5000																								
232				DR7	L	> 5000				DR9	L	2000-5000																		
242				DR7	L	> 5000				DR9	L	2000-5000					DR51	L	< 2000					DQ5	L	2000-5000				
252																														
267				DR7	L	> 5000				DR9	L	< 2000												DR53	L	> 5000				
268				DR7	L	> 5000																								
273	DR14	L	2000-5000	DR7	L	> 5000				DR9	L	2000-5000					DR51	L	< 2000					DQ5	L	> 5000				
277	DR14	L	< 2000	DR7	L	> 5000				DR9	L	< 2000					DR51	L	< 2000					DQ5	L	2000-5000	DQ6	L	< 2000	
284	DR14	L	< 2000	DR7	L	> 5000				DR9	L	2000-5000					DR51	L	< 2000					DQ5	L	2000-5000	DQ6	L	< 2000	
292	DR14	L	2000-5000	DR7	L	> 5000				DR9	L	2000-5000					DR51	L	2000-5000					DQ5	L	> 5000	DQ6	L	2000-5000	
293				DR7	L	> 5000																			DQ5	L	< 2000			
294				DR7	L	> 5000				DR9	L	< 2000																		
302								DR8	L	< 2000		DR10	L	< 2000		DR51	L	2000-5000												

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/201:

DESPATCHED ON 17TH APRIL 2016

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

HLA specificity for assessment

Lab no.	Consensus % reported	DQ2 Present 95.9%			DQ7 Absent 2.7%			DQ8 Absent 4.1%			DQ9 Absent 4.1%			DQ4 Absent 1.4%		
		spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9		DQ2	L	> 5000												
11		DQ2	L	> 5000												
12		DQ2	L	> 5000												
14		DQ2	L	> 5000												
15		DQ2	L	> 5000												
19		DQ2	L	> 5000												
20		DQ2	L	> 5000												
23		DQ2	L	> 5000												
24		DQ2	L	> 5000												
25		DQ2	L	> 5000												
26		DQ2	L	> 5000												
28		DQ2	L	> 5000												
34		DQ2	L	> 5000												
35		DQ2	L	> 5000												
38		DQ2	L	> 5000												
39		DQ2	L	> 5000												
41		DQ2	L	> 5000												
42		DQ2	L	> 5000												
45		DQ2	L	> 5000												
48		DQ2	L	> 5000												
51		DQ2	L	> 5000												
54		DQ2	L	> 5000												
58		DQ2	L	> 5000												
62		DQ2	L	> 5000												
100		DQ2	L	> 5000												
112		DQ2	L	> 5000												
114		DQ2	L	> 5000												
116		DQ2	L	> 5000												
117		DQ2	L	> 5000												
119		DQ2	L	> 5000												
120		DQ2	L	> 5000												
133		DQ2	L	> 5000												
136		DQ2	L	> 5000												
142		DQ2	L	> 5000												
143		DQ2	L	> 5000												
145		DQ2	L	> 5000												
149		DQ2	L	> 5000												
157		DQ2	L	> 5000												
160		DQ2	L	> 5000												
162		DQ2	L	> 5000												
165		DQ2	L	> 5000												
169		DQ2	L	> 5000												
181		DQ2	L	> 5000												
185		DQ2	L	> 5000												
194		DQ2	L	> 5000												
195		DQ2	L	> 5000												
197		DQ2	L	> 5000						DQ9	L	> 5000				
206		DQ2	L	> 5000				DQ8	L	> 5000						
212		DQ2	L	> 5000												
214		DQ2	L	> 5000												
216		DQ2	L	> 5000												
218		DQ2	L	2000-5000												
222		DQ2	F				DQ8	F		DQ9	F					
227		DQ2	L	> 5000												
229		DQ2	L	> 5000												
230		DQ2	L	> 5000												
232		DQ2	L	> 5000												
242		DQ2	L	> 5000												
252		DQ2	L	> 5000												
267		DQ2	L	> 5000												
268		DQ2	L	> 5000												
273		DQ2	L	> 5000												
277		DQ2	L	> 5000	DQ7	L	< 2000									
284		DQ2	L	> 5000												
292		DQ2	L	> 5000												
293		DQ2	L	> 5000												
294		DQ2	L	> 5000												
302		DQ2	L	> 5000	DQ7	L	2000-5000	DQ8	L	> 5000	DQ9	L	2000-5000	DQ4	L	< 2000
303		DQ2	L	> 5000												
309		DQ2	L	> 5000												
351		DQ2	L	> 5000												
361		DQ2	L	> 5000												
392		DQ2	L	> 5000												

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

70	< 2000	2	< 2000	3	< 2000	3	< 2000	1	< 2000
73	0	73	0	73	0	73	0	73	0
	2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
	1		1		0		1		0
	> 5000		> 5000		> 5000		> 5000		> 5000
	68		0		2		1		0

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 11 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

DPB1* Antibodies - ASSESSED												
Lab no.	14:01 Present 79.5%			17:01 Present 78.1%			19:01 Present 84.9%			20:01 Not Assessed 61.6%		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
11	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
12	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
14	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
15	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
19	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
20	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
23	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
24	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
25	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
26	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
28	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
34	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
35	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
38	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
39	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
41	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
42	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
45	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
48	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
51	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
54	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
58	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
62	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
100	14:01	L	2000-5000	17:01	L	2000-5000	19:01	L	2000-5000	20:01	L	> 5000
112	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
114							19:01	L	> 5000			
116	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
117							19:01	L	> 5000			
119	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
120	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
133	14:01	L	2000-5000	17:01	L	2000-5000	19:01	L	2000-5000			
136							19:01	L	> 5000			
142	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
143												
145	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
149	14:01	L	2000-5000	17:01	L	2000-5000	19:01	L	2000-5000			
157	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
160							19:01	L	> 5000			
162	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
165	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
169							19:01	L	> 5000			
181	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
185	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000			
194	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
195	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
197												
206	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
212												
214	14:01	L	> 5000	17:01	L	2000-5000	19:01	L	> 5000			
216												
218	14:01	L	2000-5000	17:01	L	2000-5000	19:01	L	2000-5000			
222	14:01	F										
227	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
229												
230												
232	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
242												
252												
267	14:01	L	2000-5000	17:01	L	2000-5000	19:01	L	2000-5000			
268	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
273	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
277	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
284	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
292	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
293	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
294	14:01	L	2000-5000	17:01	L	2000-5000	19:01	L	2000-5000			
302												
303	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
309	14:01	L	2000-5000	17:01	L	2000-5000	19:01	L	2000-5000			
351	14:01	L	> 5000	17:01	L	> 5000	19:01	L	> 5000	20:01	L	> 5000
361	14:01	L	2000-5000	17:01	L	2000-5000	19:01	L	2000-5000			
392												

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

58	< 2000	57	< 2000	62	< 2000	45	< 2000
73	0	73	0	73	0	73	0
	2000-5000		2000-5000		2000-5000		2000-5000
8		9		8		0	
> 5000		> 5000		> 5000		> 5000	
49		48		54		45	

NEQ-120

Issue 3

UK NEQAS for H+I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 13 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H+I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

DQA1* Antibodies - NOT ASSESSED

Consensus % reported	01:01 Not Assessed 8.2%			02:01 Absent 2.7%			03:01 Absent 4.1%			03:03 Absent 2.7%			04:01 Absent 2.7%			05:01 Not Assessed 23.3%			05:03 Absent 1.4%			05:05 Not Assessed 6.8%			06:01 Absent 1.4%		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
11																											
12																											
14	01:01	L	2000-5000												05:01	L	> 5000										
15																											
19	01:01	L	2000-5000																								
20																											
23																											
24																											
25																											
26																											
28																		05:01	L	< 2000							
34																											
35	01:01	L	2000-5000	02:01	L	> 5000	03:01	L	> 5000				04:01	L	> 5000	05:01	L	> 5000									
38																											
39																											
41																											
42										03:03	L	< 2000											05:05	L	< 2000		
45																											
48																											
51																											
54																											
58																											
62																											
100																											
112																											
114																											
116																	05:01	L	> 5000								
117																											
119																	05:01	L	> 5000					05:05	L	< 2000	
120																											
133																											
136																											
142	01:01	L	2000-5000														05:01	L	> 5000				05:05	L	< 2000		
143																											
145																											
149																											
157																											
160																	05:01	L	> 5000								
162																	05:01	L	> 5000								
165																											
169	01:01	L	> 5000				03:01	L	> 5000								05:01	L	> 5000						06:01	L	> 5000
181																											
185																	05:01	L	< 2000								
194																											
195																											
197																											
206																											
212																											
214																											
216																											
218																											
222																											
227																											
229																											
230																											
232																											
242																											
252																											
267																											
268																											
273																											
277																											
284																	05:01	L	> 5000					05:05	L	< 2000	
292																	05:01	L	> 5000					05:05	L	< 2000	
293																											
294																											
302																											
303																											
309																	05:01	L	> 5000								
351	01:01	L	2000-5000	02:01	L	> 5000	03:01	L	> 5000																		
361																	04:01	L	> 5000								
362																											

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	6	< 2000	2	< 2000	3	< 2000	2	< 2000	2	< 2000	17	< 2000	1	< 2000	5	< 2000	1	< 2000
Total Participants	73	0	73	0	73	0	73	0	73	0	73	0	73	0	73	5	73	0
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		5		0		0		0		0		0		1		0		0
		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000
		1		2		3		0		2		15		0		0		1

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 14 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	01:03 Not Assessed 6.8%			01:05 Absent 4.1%			02:01 Not Assessed 15.1%			02:02 Not Assessed 20.5%			03:01 Not Assessed 20.5%		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9															
11															
12															
14															
15															
19															
20															
23															
24															
25															
26															
28															
34															
35	01:03	L	> 5000	01:05	L	> 5000	02:01	L	> 5000	02:02	L	> 5000	03:01	L	> 5000
38															
39															
41															
42															
45															
48															
51															
54															
58															
62															
100	01:03	L	2000-5000				02:01	L	2000-5000						
112															
114							02:01	L	> 5000	02:02	L	> 5000	03:01	L	> 5000
116															
117							02:01	L	> 5000	02:02	L	> 5000	03:01	L	> 5000
119															
120															
133															
136							02:01	L	> 5000	02:02	L	> 5000	03:01	L	> 5000
142	01:03	L	> 5000				02:01	L	> 5000	02:02	L	> 5000	03:01	L	> 5000
143															
145															
149															
157													03:01	L	> 5000
160							02:01	L	> 5000	02:02	L	> 5000	03:01	L	> 5000
162															
165															
169							02:01	L	> 5000	02:02	L	> 5000	03:01	L	> 5000
181															
185															
194															
195															
197															
206															
212															
214															
216															
218															
222															
227															
229															
230															
232	01:03	L	> 5000	01:05	L	> 5000	02:01	L	> 5000	02:02	L	> 5000	03:01	L	> 5000
242															
252															
267															
268															
273							02:01	L	> 5000	02:02	L	> 5000	03:01	L	> 5000
277										02:02	L	> 5000	03:01	L	> 5000
284															
292										02:02	L	> 5000	03:01	L	> 5000
293															
294															
302															
303										02:02	L	> 5000	03:01	L	> 5000
309										02:02	L	2000-5000			
351	01:03	L	> 5000	01:05	L	> 5000	02:01	L	> 5000	02:02	L	> 5000	03:01	L	> 5000
361															
392															

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	5	< 2000	3	< 2000	11	< 2000	15	< 2000	15	< 2000
Total Participants	73	0	73	0	73	0	73	0	73	0
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		1		0		1		1		0
		> 5000		> 5000		> 5000		> 5000		> 5000
		4		3		10		14		15

NEQ-120

Issue 3

UK NEQAS for H+I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 15 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H+I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 302/2016

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	Technique used	Sample Treatment	High Background	Neg control serum batch	Allele Specific Antibodies IgG	Luminex kit (lot)		Control bead MFI		Luminex kit (lot)		Cut-off value		Control bead MFI		Luminex kit (lot)		Cut-off value	
						IgG	IgG	IgG	IgG	IgG	IgG	Positive	Negative	IgG	IgG	Positive	Negative		
9	L	EDTA	No	18	DOB*1*05:01	LSAII	1500	9500	150	LSM12	2.5	4577	367						
11	L	EDTA	No	18	LS2A01	LS2A01	1000	3232	222										
12	L	EDTA	No	18	DOB*1*05:01	LS2A01	500	9725	119										
14	L	Heat Inactivation, EDTA	No	18	DQA*1*01:01	LS2A01	1500	11578	117										
15	L	EDTA	No		DOB*1*05:01	LS2A01	1000	8990	72.11										
19	L	None	No		DOB*1*05:01	LS2A01	1000	10035	85										
20	C+L	EDTA	No	19	DOB*1*05:01	LS2A01	1000	10448	128										
23	L	EDTA	No		DRB1*14:02	LS2A01	1000	13070	179										
24	L	EDTA	Yes	18	DOB*1*05:01, 06:01	LS2A01	1000	11855	150	LSM12	4.5	11491	813	LS2PRA	1000	11147	629		
25	L	EDTA		19	DRB5*02	LS2A01	1000	9031	153	LSM12	6.1	14124	206	LSAII	1500	21044	271		
26	L	EDTA	No	19	DOB*1*05:01	LS2A01	2209	9244	120	LSM12	4.5	14161	451						
28	L	None	No		DRB1*14:02, 15:03	LS2A01	500	7583	108										
34	L	EDTA	No	18	DOB*1*05:01	LS2A01	1037839	11278	39										
35	L	EDTA	No	19	DRB5*02:02	LS2A01	1000	10962	32										
38	L	EDTA	No	18	LSAII	LSAII	2200	9474	32	LSAII	16959	682							
39	L	EDTA	No	18	DOB*1*05:01	LS2A01	2200	7965	90										
41	L	EDTA	No	18	DPA*1*02:02, 03:01	LS2A01	2000	9759	33										
42	L	EDTA	No	19	DOB*1*05:01	LS2A01	500	11973	142										
45	L	EDTA	No		DRB5*02:02	LS2A01	1500	13000	30										
48	L	Heat Inactivation	No	19	DQA*1*05:03	LS2A01	1500	13000	30										
51	L	EDTA	No		DOB*1*05:01, 06:01	LS2A01	2400	11822	253										
54	L	EDTA	No	18	DRB1*01:01, 14:02	LS2A01	1000	7754	157										
58	L	EDTA	No	18	DRB5*02:02	LS2A01	1000	10561	79										
62	L	None	No	19	DOB*1*05:01	LS2A01	>1500	12729	95										
100	L	None	No	3006101	LSAII	1748	15476	120											
112	L	None	No	3005657	LSAII	500	18455	243											
114	L	EDTA	No		DRB1*14:02	LS2A01	1000	5587	69										
116	L	EDTA, Adsorption	Yes	18	DRB1*09:02, 14:02	LS2A01	1000	8214	84	LSM12		7516	355						
117	L	None	No	18	DOB*1*05:01	LS2A01	500	7772	75										
119	L	EDTA	Yes	17	DOB*1*05:01	LS2A01	>1000	12827	60	LSM12	>1.5	14055	175						
120	L	EDTA	No		DRB5*02:02	LS2A01	500	8751	56										
133	L	Heat Inactivation	No	3005855	DOB*1*05:01, 06:01	LSAII	16142	110											
136	L	None	No		DRB1*01:01, 14:02	LS2A01	1000	14122	127										
142	L	EDTA	No		DRB5*02:02	LS2A01	1000	11573	65										
143	L	None	No		DOB*1*05:01	LS2A01	1000	14211	284										
145	L	None	No	16	DRB5*02:02, 14:02	LS2A01	1000	9827	53										
149	L	None	No		DOB*1*05:01	LSAII	1000	19473	380										
157	L	EDTA	No	18	DOB*1*05:01	LS2A01	1000	7142.8	57.6										
160	L	Adsorption	No	17	DRB1*14:02	LS2A01	950	7014	40.4										
162	L	EDTA	No		DRB1*09:02	LS2A01	1000	10680	157	LSM12	3	7949	289						
165	L	None	No		DOB*1*05:01	LS2A01	101	7320	71										
169	L	None	No		DOB*1*05:01	LS2A01	1000	3532	65										
181	L	None	No	18	LSAII	LS2A01	500	7740	140										
185	L	EDTA	No		LSAII	LSAII	2	19042	179	LM2	2	21620	385	LMX	1	19522	114		
194	L	EDTA	No		DRB1*14:02	LS2A01	1000	11274	100										
195	L	None	No		DOB*1*05:01	LS2A01	1000	8803	54										
197	L	None	No		DOB*1*05:01	LS2A01	1000	12745	135										
206	L	EDTA	No		LM2	LM2	1500	18035	128										
212	L	None	No		LSAII	LSAII	750	16560	251										
214	L	None	Yes		DPB*1*01:03, 01:05, 01:06, 01:09, 01:11, 01:13, 01:14, 01:17, 01:19, 01:01, 01:02, 02:04, 01:05, 07:01, 09:01	LSAII	750	16560	251										
216	L	None	No	3005889	DOB*1*02:01:02	LM2	3000	17532	296										
218	L	None	No		DRB1*04:01-05, 07:01, 09:01	LSAII	750	16518	251										
222	F	None	No		DOB*1*05:01	LSAII	1000	11578	117										
227	L	Dilution, EDTA	No		DOB*1*05:01	LSAII	1000	11578	117										
229	L	None	No	3005889	LM2	1000	>10000	155											
232	L	None	No	18	LSAII	LS2A01	1200	7509	50										
232	L	Adsorption	No		DRB1*03	LSAII	22416	448											
252	L	None	No		LSAII	LSAII	2	22199	324										
267	L	EDTA	No		LSAII	LSAII	700	13203	148										
268	C+L	EDTA	No	18	LSAII	LS2A01	2000	9691	18	LS2PRA	2000	9025	391						
273	L	None	No		DRB1*14:02	LS2A01	1000	1184	129										
277	L	EDTA	No	19	DRB5*02	LS2A01	500	7891	55										
284	L	None	No		DOB*1*05:01, 06:01	LS2A01	1000	9824	72.3										
292	L	EDTA, Adsorption	No	18	DRB1*14:02, 15:03	LS2A01	500	14905	77	LSM12	2.5	13720	46						
293	L	None	No		DRB5*02:02	LS2A01	500	6017	29.8										
294	L	None	No		DQA*1*05:03	LSAII	1500	13433											
302	L	None	No		DOB*1*05:01	LSAII	1000	9310	216										
303	L	Heat Inactivation, EDTA	No	18	DRB1*05:01	LSAII	1000	16500	120										
309	L	None	No		LSAII	LSAII	560	10153	159										
351	L	EDTA	No	18	LSAII	LSAII	500	16302	132										
361	L	None	No	3006101	LSAII	LSAII	500	16302	132										
362	L	None	No		LSAII	LSAII	500	16302	132										

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 16 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 303/201:

DESPATCHED ON 17TH APRIL 2016

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

HLA specificity for assessment

Lab no.	DQ7 Present 95.9%			DQ8 Present 95.9%			DQ9 Present 95.9%			DQ4 Absent 2.7%		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
11	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
12	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
14	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
15	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
19	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
20	DQ7	C+L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
23	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
24	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
25	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
26	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
28	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
34	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
35	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
38	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
39	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
41	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
42	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
45	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
48	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
51	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
54	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
58	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
62	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
100	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
112	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
114	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
116	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
117	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
119	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
120	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
133	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
136	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
142	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
143	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
145	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
149	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
157	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
160	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
162	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
165	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
169	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
181	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
185	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
194	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
195	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
197	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
206	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
212	DQ7	L	2000-5000	DQ8	L	> 5000	DQ9	L	> 5000			
214	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
216	DQ7	L	2000-5000	DQ8	L	> 5000	DQ9	L	> 5000	DQ4	L	2000-5000
218	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
222	DQ7	F	> 5000	DQ8	F	> 5000	DQ9	F	> 5000			
227	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
229												
230	DQ7	L	2000-5000	DQ8	L	> 5000	DQ9	L	> 5000			
232	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
242												
252	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
267	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
268	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
273	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
277	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
284	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
292	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
293	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
294	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
302	DQ7	L	2000-5000	DQ8	L	> 5000	DQ9	L	> 5000	DQ4	L	> 5000
303	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
309	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
351	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
361	DQ7	L	> 5000	DQ8	L	> 5000	DQ9	L	> 5000			
392												

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Lab no.	Consensus % reported	DQ7 Present 95.9%	DQ8 Present 95.9%	DQ9 Present 95.9%	DQ4 Absent 2.7%
70	< 2000				
73	0				
4	2000-5000				
65	> 5000				
70	< 2000				
73	0				
0	2000-5000				
69	> 5000				
2	< 2000				
73	0				
0	2000-5000				
1	> 5000				
1	> 5000				

NEQ-120

Issue 3

UK NEQAS for H+I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 18 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H+I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 303/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	10:01 Absent 4.1%			14:01 Not Assessed 31.5%		
	spec	tech	MFI	spec	tech	MFI
9				14:01	L	< 2000
11						
12	10:01	L	< 2000	14:01	L	2000-5000
14						
15				14:01	L	< 2000
19						
20				14:01	L	< 2000
23						
24				14:01	L	2000-5000
25				14:01	L	< 2000
26						
28	10:01	L	< 2000	14:01	L	< 2000
34						
35						
36						
39						
41						
42				14:01	L	< 2000
45						
48						
51						
54				14:01	L	< 2000
58				14:01	L	< 2000
62				14:01	L	2000-5000
100						
112						
114						
116						
117				14:01	L	< 2000
119						
120				14:01	L	< 2000
133						
136	10:01	L	< 2000	14:01	L	2000-5000
142						
143						
145						
149						
157						
160						
162						
165						
169						
181				14:01	L	< 2000
185						
194				14:01	L	< 2000
195				14:01	L	< 2000
197						
206				14:01	L	< 2000
212						
214						
216						
218						
222				14:01	F	
227				14:01	L	< 2000
229						
230						
232						
242						
252						
267						
268						
273				14:01	L	2000-5000
277						
284				14:01	L	2000-5000
292				14:01	L	< 2000
293						
294						
302						
303						
309						
351						
361						
392						

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	3	< 2000	23	< 2000
Total Participants	73	3	73	16
		2000-5000		2000-5000
		0		6
		> 5000		> 5000
		0		0

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 19 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 303/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	01:01 Absent 1.4%			02:01 Absent 4.1%			03:01 Not Assessed 13.7%			03:02 Not Assessed 20.5%			03:03 Absent 1.4%			05:01 Absent 1.4%			05:05 Not Assessed 16.4%			06:01 Not Assessed 17.8%			
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	
11																									
12																									
14							03:01	L	> 5000	03:02	L	> 5000						05:05	L	> 5000	06:01	L	> 5000		
15																									
19																									
20																									
23																									
24																									
25																									
26																									
28																									
34				02:01	L	> 5000	03:01	L	> 5000	03:02	L	> 5000													
35																									
36																									
39																									
41																									
42																									
45																									
48																									
51																									
54																									
58																									
62																									
100																									
112																									
114							03:01	L	> 5000	03:02	L	> 5000						05:05	L	> 5000	06:01	L	> 5000		
116																									
117							03:01	L	> 5000	03:02	L	> 5000						05:05	L	> 5000	06:01	L	> 5000		
119																									
120																									
133																									
136							03:01	L	> 5000	03:02	L	> 5000						05:05	L	> 5000	06:01	L	> 5000		
142										03:02	L	> 5000													
143																									
145																									
149																									
157										03:02	L	> 5000						05:05	L	> 5000	06:01	L	> 5000		
160							03:01	L	> 5000	03:02	L	> 5000						05:05	L	> 5000	06:01	L	> 5000		
162																									
165																									
169							03:01	L	> 5000	03:02	L	> 5000						05:05	L	> 5000	06:01	L	2000-5000		
181																									
185																									
194																									
195																									
197																									
206																									
212		01:01	L	< 2000																					
214																									
216																									
218																									
222																									
227																									
229																									
230																									
232				02:01	L	> 5000	03:01	L	> 5000	03:02	L	> 5000						05:05	L	2000-5000	06:01	L	2000-5000		
242																									
252																									
267																									
268																									
273							03:01	L	> 5000	03:02	L	> 5000						05:05	L	> 5000	06:01	L	> 5000		
277										03:02	L	> 5000						05:05	L	> 5000	06:01	L	> 5000		
284																									
292										03:02	L	> 5000	03:03	L	< 2000			05:05	L	> 5000	06:01	L	> 5000		
293																									
294																									
302																									
303										03:02	L	> 5000						05:05	L	> 5000	06:01	L	> 5000		
309																									
351				02:01	L	> 5000	03:01	L	> 5000	03:02	L	> 5000			05:01	L	> 5000				06:01	L	> 5000		
361																									
392																									

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	1	< 2000	3	< 2000	10	< 2000	15	< 2000	1	< 2000	1	< 2000	12	< 2000	13	< 2000
Total Participants	73	1	73	0	73	0	73	0	73	1	73	0	73	0	73	0
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		0		0		0		0		0		0		1		2
		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000
		0		3		10		15		0		1		11		11

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 20 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

DPA1* Antibodies - NOT ASSESSED

Consensus % reported	Lab no.	Result
9		No Specificities found
11		No Specificities found
12		No Specificities found
14		No Specificities found
15		No Specificities found
19		No Specificities found
20		No Specificities found
23		No Specificities found
24		No Specificities found
25		No Specificities found
26		No Specificities found
28		No Specificities found
34		No Specificities found
35		No Specificities found
38		No Specificities found
39		No Specificities found
41		No Specificities found
42		No Specificities found
45		No Specificities found
48		No Specificities found
51		No Specificities found
54		No Specificities found
58		No Specificities found
62		No Specificities found
100		No Specificities found
112		No Specificities found
114		No Specificities found
116		No Specificities found
117		No Specificities found
119		No Specificities found
120		No Specificities found
133		No Specificities found
136		No Specificities found
142		No Specificities found
143		No Specificities found
145		No Specificities found
149		No Specificities found
157		No Specificities found
160		No Specificities found
162		No Specificities found
165		No Specificities found
169		No Specificities found
181		No Specificities found
185		No Specificities found
194		No Specificities found
195		No Specificities found
197		No Specificities found
206		No Specificities found
212		No Specificities found
214		No Specificities found
216		No Specificities found
218		No Specificities found
222		No Specificities found
227		No Specificities found
229		No Specificities found
230		No Specificities found
232		No Specificities found
242		No Specificities found
252		No Specificities found
267		No Specificities found
268		No Specificities found
273		No Specificities found
277		No Specificities found
284		No Specificities found
292		No Specificities found
293		No Specificities found
294		No Specificities found
302		No Specificities found
303		No Specificities found
309		No Specificities found
351		No Specificities found
361		No Specificities found
392		No Specificities found

Technique : C = CDC; E = ELISA; F = Flow cytometry

No. Reporting Spec
Total Participants

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 21 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 303/2018
DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	Techniques used IgG	Sample Treatment IgG	High Background	Neg control serum batch	Allele Specific Antibodies		Luminex kit (lot)		Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)		Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative
					IgG	IgG	IgG	IgG			IgG	IgG						
9	L	EDTA	No			LSAII	800	6500	350									
11	L	EDTA	No	18		LS2A01	1000	5082	465		LSM12	2.5	7307	292				
12	L		No	18		LS2A01	500	14055	541									
14	L	EDTA, Heat Inactivation	No	18		LS2A01	1500	14932	262									
15	L	EDTA	No	18	DRB1*04:01, 04:04	LS2A01	1000	11909.38	442.07									
19	L	None	No			LS2A01	1000	10092	219									
20	C+L	EDTA, Adsorbion	Yes			LS2A01	1000	14756	425									
23	L	EDTA	No	19		LS2A01	1000	11991	163									
24	L	EDTA	Yes	18		LS2A01	1000	15015	330		LSM12	4.5	13758	1429	LS2PRA	1000	13221	1707
25	L	EDTA	No	19		LS2A01	1000	9508	406		LSM12	6.1	16513	395	LSAII	1500	15104	122
26	L	EDTA, Adsorbion	Yes	19		LS2A01	1046	11272	230		LSM12	4.5	17878	1456				
28	L	None	No			LS2A01	500	12367	379									
34	L	EDTA	No	18		LS2A01	1039/570	11073	197									
35	L	EDTA	No	19		LS2A01	100	14137	219									
38	L	EDTA	No	18		LS2A01		11907	160		LSAII		16416	339				
39	L	EDTA	No	18		LS2A01	900	8837	232									
41	L		No	18		LS2A01	2000	6614	157									
42	L		No	19		LS2A01	500	12102	254									
45	L	EDTA, Adsorbion	No			LS2A01	1500	14000	270									
48	L	Heat Inactivation	No	19														
51	L	EDTA	No			LS2A01	1300	9032	572									
54	L	EDTA	No	18		LS2A01	1000	9103	228									
58	L	EDTA	No	18		LS2A01	1000	11741	242									
62	L		No	19		LS2A01	>1500	16444	179									
100	L	None	No	3006101		LSAII	1369	16518	187									
112	L	None	No	3005857		LSAII	500	19324	217									
114	L	EDTA	No			LS2A01	1000	5817	65									
116	L	EDTA, Adsorbion	Yes	18		LS2A01	1000	11453	129		LSM12		8722	574				
117	L	None	No	18	DQA1*05:03 >5000	LS2A01	500	10251	138									
119	L	EDTA	Yes	17		LS2A01	>1000	17680	109		LSM12	>1.5	15566	220				
120	L	EDTA	No			LS2A01	500	11630	114									
133	L	Heat Inactivation	No	3005855	DRB1*04:01/02/03/04/05 DQB1*03:01/02/03	LSAII		16004	116									
136	L	None	No		DQA1*05:03	LS2A01	1000	18121	300									
142	L	EDTA	No			LS2A01	1000	5064	191									
143	L	None	No			LS2A01	1000	25157	661									
145	L	None	No	16		LS2A01	1000	10875	87									
149	L	None	No			LSAII	1000	20480	316									
157	L	EDTA	No			LS2A01	1000	9419.4	87.97									
160	L	Adsorbion	No	17		LS2A01	1000	9090	31.5									
162	L	EDTA	No			LS2A01	1000	10523	167		LSM12	3	8352	207				
165	L	None	No			LS2A01	70	8592	121									
169	L	None	No		DQA1*05:03	LS2A01	1000	6563	151									
181	L	None	No	18		LS2A01	500	9966	226									
185	L	Heat Inactivation	No			LM2	2	21188	153									
194	L	EDTA	No			LS2A01	1000	11861	201		LMX	1	19230	91	LSAII	2	20143	179
195	L	None	No			LS2A01	1000	9419	117									
197	L																	
206	L	EDTA	No			LS2A01	1000	10297	102									
212	L	None	No			LM2	1500	18669	136									
214	L	None	Yes		DQA1*01:01 DQB1*03:01-03/04:01-05	LSAII	750	15691	248									
216	L	None	No	3005989		LM2	4000	17422	192									
218	L	None	No		DRB1*04:01-05 DQB1*03:01-03													
222	L	None																
227	L	Dilution, EDTA	No															
229	L																	
230	L	None	No	3005989		LM2	1000	>10000	155									
232	L	None	No	18		LS2A01	1200	8049	158									
242	L	Adsorbion	No		DQB1*03	LSAII		20871	194									
252	L	None	No			LM2	2	22124	251									
267	L	EDTA	No			LSAII	700	13907	158									
268	C+L	EDTA	No	18		LS2A01	2000	9021	73		LS2PRA	2000	9472	340				
273	L	None	No		DQA1*05:03	LS2A01	1500	12856	347									
277	L	EDTA	No	19	DQA1*05:03	LS2A01	500	7654	72									
284	L	EDTA	No			LS2A01	1000	9252	155.32									
292	L	EDTA	Yes	18	DQA1*05:03	LS2A01	500	14350	517		LSM12	2.5	13192	194				
293	L	None	No			LS2A01	500	8921	42.3									
294	L	None	No			LSAII		12860										
302	L																	
303	L				DQA1*05:03	LS2A01	1000	9945	179									
309	L	None	No			LSAII	700	16037	125									
351	L	EDTA	No	18		LS2A01	1500	12258	252									
361	L	None	No	3006101		LSAII	500	17782	70									
392																		

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

NEQ-120

Issue 3

UK NEQAS for H+I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 22 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H+I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/201:

DESPATCHED ON 17TH APRIL 2016

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

HLA specificity for assessment																														
Lab no.	DR1 Absent 2.7%			DR103 Absent 1.4%			DR15 Present 89.0%			DR16 Present 83.6%			DR12 Absent 2.7%			DR13 Absent 1.4%			DR14 Absent 1.4%			DR7 Absent 2.7%			DR9 Absent 1.4%			DR10 Present 93.2%		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9																														
11																														
12																														
14																														
15																														
19																														
20																														
23																														
24																														
25																														
26																														
28																														
34																														
35																														
38																														
39																														
41																														
42																														
45																														
48																														
51																														
54																														
58																														
62																														
100																														
112																														
114																														
116																														
117																														
119																														
120																														
133																														
136																														
142																														
143																														
145																														
149																														
157																														
160																														
162																														
165																														
169																														
181																														
185																														
194																														
195																														
197																														
206																														
212																														
214																														
216																														
218																														
222																														
227																														
229																														
230																														
232																														
242																														
252																														
267																														
268																														
273																														
277																														
284																														
292																														
293																														
294																														
302																														
303																														
309																														
351																														
361																														
392																														

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	2	< 2000	1	< 2000	65	< 2000	61	< 2000	2	< 2000	1	< 2000	1	< 2000	2	< 2000	1	< 2000	68	< 2000
Total Participants	73	1	73	0	73	9	73	22	73	0	73	0	73	1	73	0	73	0	73	0
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		0		0		50		37		1		0		0		0		0		28
		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000
		0		0		5		2		0		0		0		2		1		39

NEQ-120

Issue 3

UK NEQAS for H+I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 23 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H+I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/201:

DESPATCHED ON 17TH APRIL 201E

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

HLA specificity for assessment

Lab no.	DR51 Absent 4.1%		DR52 Absent 1.4%		DR53 Present 86.3%		DQ5 Present 94.5%		DQ6 Present 94.5%		DQ2 Absent 1.4%		DQ7 Absent 1.4%		DQ8 Absent 1.4%		DQ9 Absent 1.4%		DQ4 Present 93.2%		
	spec	tech	spec	tech	spec	tech	spec	tech	spec	tech	spec	tech	spec	tech	spec	tech	spec	tech	spec	tech	
9																					
11																					
12																					
14																					
15																					
19																					
20																					
23																					
24																					
25																					
26																					
28																					
34																					
35																					
38																					
39																					
41																					
42																					
45																					
48																					
51																					
54																					
58																					
62																					
100																					
112																					
114																					
116																					
117																					
119																					
120																					
133																					
136																					
142																					
143																					
145																					
149																					
157																					
160																					
162																					
165																					
169																					
181																					
185																					
194																					
195																					
197																					
206																					
212																					
214																					
216																					
218																					
222																					
227																					
229																					
230																					
232																					
242																					
252																					
267																					
268																					
273																					
277																					
284																					
292																					
293																					
294																					
302																					
303																					
309																					
351																					
361																					
392																					

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

3	< 2000	1	< 2000	63	< 2000	69	< 2000	69	< 2000	1	< 2000	1	< 2000	1	< 2000	1	< 2000	68	< 2000
73	2	73	0	12	73	0	73	0	73	0	73	1	0	73	0	73	0	13	73
	2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
	1		41		8		8		8		0		0		1		0		27
	> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000
	0		1		10		60		60		1		0		0		0		27

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 24 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

DPB1* Antibodies - ASSESSED

Lab no.	01:01 Not Assessed 31.5%			03:01 Not Assessed 6.8%			05:01 Not Assessed 28.8%			06:01 Not Assessed 19.2%			11:01 Absent 1.4%		14:01 Absent 1.4%		17:01 Absent 2.7%		18:01 Absent 1.4%			
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	
11																						
12	01:01	L	< 2000																			
14																						
15																						
19																						
20	01:01	L	< 2000	03:01	L	< 2000	05:01	L	< 2000	06:01	L	< 2000										
23																						
24																						
25	01:01	L	< 2000				05:01	L	< 2000	06:01	L	< 2000										
26																						
28	01:01	L	< 2000																			
34							05:01	L	< 2000	06:01	L	< 2000										
35																						
36																						
38																						
39																						
41																						
42	01:01	L	< 2000							06:01	L	< 2000										
45																						
48																						
51	01:01	L	2000-5000	03:01	L	2000-5000	05:01	L	2000-5000	06:01	L	2000-5000										
54	01:01	L	< 2000																			
58	01:01	L	< 2000				05:01	L	< 2000	06:01	L	< 2000										
62																						
100																						
112																						
114																						
116	01:01	L	< 2000				05:01	L	< 2000	06:01	L	< 2000										
117	01:01	L	< 2000				05:01	L	< 2000													
119																						
120	01:01	L	< 2000																			
133																						
136	01:01	L	< 2000				05:01	L	2000-5000													
142	01:01	L	< 2000				05:01	L	< 2000	06:01	L	< 2000										
143																						
145	01:01	L	< 2000																			
149																						
157	01:01	L	< 2000				05:01	L	< 2000													
160							05:01	L	< 2000													
162																						
165																						
169																						
181	01:01	L	< 2000				05:01	L	< 2000													
185																						
194																						
195							05:01	L	< 2000													
197																						
206																						
212	01:01	L	< 2000							06:01	L	< 2000				14:01	L	< 2000	17:01	L	< 2000	
214																						
216																						
218																						
222																						
227	01:01	L	2000-5000	03:01	F	< 2000	05:01	L	2000-5000	06:01	L	< 2000	11:01	F						18:01	F	
229																						
230																						
232																						
242																						
252																						
267																						
268																						
273	01:01	L	2000-5000				05:01	L	2000-5000													
277																						
284	01:01	L	2000-5000				05:01	L	2000-5000	06:01	L	< 2000										
292	01:01	L	2000-5000							06:01	L	2000-5000										
293																						
294																						
302																						
303	01:01	L	< 2000																			
309																						
351							05:01	L	< 2000													
361																						
392																						

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	23	< 2000	5	< 2000	21	< 2000	14	< 2000	1	< 2000	1	< 2000	2	< 2000	1	< 2000
Total Participants	73	18	73	3	73	15	73	11	73	0	73	1	73	2	73	0
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		5		1		6		3		0		0		0		0
		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000
		0		0		0		0		0		0		0		0

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 25 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	DQA1* Antibodies - NOT ASSESSED																				
	01:01 Not Assessed 30.1%			01:02 Not Assessed 32.9%			01:03 Not Assessed 30.1%			01:04 Not Assessed 11.0%			02:01 Absent 2.7%			03:03 Not Assessed 17.8%			04:01 Absent 4.1%		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
11																					
12																					
14	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000						03:03	L	> 5000				
15																					
19																					
20																					
23																					
24																					
25																					
26																					
28																					
34																					
35	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000				02:01	L	2000-5000	03:03	L	2000-5000	04:01	L	2000-5000
36																					
38																					
39																03:03	L	2000-5000			
41																					
42																					
45																					
48																					
51																					
54																					
58																					
62																					
100																					
112	01:01	L	> 5000	01:02	L	2000-5000	01:03	L	2000-5000	01:04	L	2000-5000									
114	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000												
116																					
117	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000						03:03	L	> 5000				
119																					
120																					
133	01:01	L	> 5000	01:02	L	> 5000	01:03	L	2000-5000	01:04	L	2000-5000									
136	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000						03:03	L	> 5000				
142	01:01	L	> 5000	01:02	L	> 5000									03:03	L	> 5000				
143																					
145	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000	01:04	L	2000-5000									
149	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000						03:03	L	> 5000				
157	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000						03:03	L	> 5000				
160	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000						03:03	L	> 5000				
162																					
165																					
169																					
181																					
185																					
194																					
195																					
197																					
206																					
212	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000	01:04	L	2000-5000									
214																					
216	01:01	L	2000-5000	01:02	L	2000-5000	01:03	L	2000-5000	01:04	L	2000-5000									
218																					
222																					
227																					
229																					
230																					
232	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000				02:01	L	2000-5000	03:03	L	2000-5000	04:01	L	2000-5000
242																					
252																					
267	01:01	L	> 5000	01:02	L	2000-5000	01:03	L	2000-5000	01:04	L	2000-5000									
268	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000												
273	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000						03:03	L	> 5000				
277	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000						03:03	L	> 5000				
284																					
292	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000												
293																					
294	01:01	L	2000-5000	01:02	L	> 5000	01:03	L	2000-5000	01:04	L	2000-5000									
302																					
303	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000						03:03	L	> 5000				
309																					
351	01:01	L	> 5000	01:02	L	> 5000	01:03	L	> 5000						03:03	L	> 5000				
361	01:01	L	2000-5000	01:02	L	> 5000	01:03	L	2000-5000	01:04	L	2000-5000							04:01	L	> 5000
392																					

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	22	< 2000	24	< 2000	22	< 2000	8	< 2000	2	< 2000	13	< 2000	3	< 2000
Total Participants	73	0	73	0	73	0	73	0	73	0	73	0	73	0
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		3		3		6		8		2		3		2
		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000
		19		21		16		0		0		10		1

NEQ-120

Issue 3

UK NEQAS for H+I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 26 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H+I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

DPA1* Antibodies - NOT ASSESSED									
Consensus % reported	01:03 Absent 4.1%			02:01 Absent 2.7%			02:02 Absent 4.1%		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
Lab no.									
9									
11									
12									
14									
15									
19									
20	01:03	L	< 2000				02:02	L	< 2000
23									
24									
25	01:03	L	< 2000						
26									
28									
34									
35									
36									
39									
41									
42									
45									
48									
51									
54									
58									
62									
100									
112									
114									
116									
117									
119									
120									
133									
136									
142	01:03	L	< 2000	02:01	L	< 2000	02:02	L	< 2000
143									
145									
149									
157									
160									
162									
165									
169									
181									
185									
194									
195									
197									
206									
212									
214									
216									
218									
222									
227									
229									
230									
232									
242									
252				02:01	L	< 2000			
267									
268									
273									
277									
284									
292									
293									
294									
302									
303									
309							02:02	L	< 2000
351									
361									
392									

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	3	< 2000	2	< 2000	3	< 2000
Total Participants	73	3	73	2	73	3
		2000-5000		2000-5000		2000-5000
		0		0		0
		> 5000		> 5000		> 5000
		0		0		0

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 27 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 304/2018

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	Techniques used IgG	Sample Treatment IgG	High Background	Neg control serum batch	Allele Specific Antibodies IgG	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative
9	L	EDTA	No			LSAII	1500	11500	100								
11	L	EDTA	No	18		LS2A01	1000	4169	88	LSM12	2.5	6791	69				
12	L					LS2A01	500	9684	52								
14	L	EDTA, Heat Inactivation	No	18		LS2A01	1500	11345	36								
15	L	EDTA	No	18		LS2A01	1000	11345	100								
19	L	None	No			LS2A01	1000	6809	73								
20	C+L	EDTA	No			LS2A01	1000	11359	71								
23	L	EDTA	No	19		LS2A01	1000	10962	31								
24	L	EDTA	No	18	DRB1*01:01, 03:01	LS2A01	1000	11500	37	LSM12	4.5	10687	343	LS2PRA	1000	11031	27
25	L	EDTA	No	19	DPB1*05:01	LS2A01	1000	9229	96	LSM12	6.1	15406	91	LSAII	1500	15591	140
26	L	EDTA	No	19	DPA1*02:02 DRB1*15:02 DRB1*15:03	LS2A01	1045	8146	54	LSM12	4.5	11127	179				
28	L	None				LS2A01	500	9594	66								
34	L	EDTA	No	18		LS2A01	1146/939	10769	26								
35	L	EDTA	No	19		LS2A01	1000	10291	25								
38	L	EDTA	No	18		LS2A01	1000	9048	31	LSAII		16447	271				
39	L	EDTA	No	18		LS2A01	1180	7334	62								
41	L	EDTA	No	18		LS2A01	2000	8691	26								
42	L	EDTA	No	19		LS2A01	500	9896	57								
45	L	EDTA, Adsorption	No			LS2A01	1500	11000	40								
48	L	Heat Inactivation	No	19													
51	L	EDTA	No			LS2A01	1800	12916	151								
54	L	EDTA	No	18		LS2A01	1000	9164	67								
58	L	EDTA	No	18		LS2A01	1000	10328	45								
62	L	None	No	19		LS2A01	>1500	11978	79	LSAII	750	15352	249				
100	L	None	No	3006101		LSAII	1346	1590	102								
112	L	None	No	3005857		LSAII	500	18180	158								
114	L	EDTA	No			LS2A01	1000	5765	25								
116	L	EDTA	No	18		LS2A01	1000	7444	67	LSM12		8303	103				
117	L	None	No	18		LS2A01	500	11755	19								
119	L	EDTA	No	17		LS2A01	>1000	9924	31	LSM12	>1.5	11486	44				
120	L	EDTA	No			LS2A01	500	9628	27								
133	L	Heat Inactivation	No	3005855	DRB1*10:01, 15:01/02/03, 16:01/02 DRB4*01:01 DQB1*04:01/02, 05:01/02/03, 06:01/02/03/04 DPB1*05:01 DPA1*02:02	LSAII	500	15382	100								
136	L	None	No			LS2A01	1000	15747	54								
142	L	EDTA	No			LS2A01	1000	11399	48								
143	L	None	No			LS2A01	1000	13779	163								
145	L	None	No	16	DPB1*05:01 DPA1*02:02	LS2A01	1000	10490	36								
149	L	None	No			LSAII	1000	17645	205								
157	L	EDTA	No	18		LS2A01	1000	7965.4	43.45								
160	L	Adsorption	No	17		LS2A01	1000	8021	24.4								
162	L	EDTA	No			LS2A01	1000	10082	35	LSM12	3	9714	50				
165	L	None	No			LS2A01	152	6407	42								
169	L	None	No	18	DPB1*05:01	LS2A01	1000	2881	35								
181	L	None	No		DPB1*02:02	LS2A01	500	8246	65								
185	L	Heat Inactivation	No			LM2	2	21628	254	LMX	1	19557	123	LSAII	2	20148	190
194	L	EDTA	No			LS2A01	1000	11671	31								
195	L	None	No			LS2A01	1000	8100	33								
197	L																
206	L	EDTA	No			LS2A01	1000	13215	14								
212	L	None	No			LM2		20593	90								
214	L		Yes		DPB1*17:01 DQA1*01:01/02/03/04 DQB1*04:01/04:02/05:01-03/06:01-04 DRB1*10:01/15:01-03/16:01/16:02 DRB4*01:01	LSAII	750	15406	228								
216	L					LM2	2000	17759	209								
218	L	None	No		DQB1*04:01/04:02/05:01-03/06:01-04 DRB1*10:01/15:01-03/16:01/16:02 DRB4*01:01	LSAII	750	17038	169								
222	F	None															
227	L	Dilution, EDTA	No														
229	L																
230	L	None	No	3005989		LM2	1000	>10000	155								
232	L	None	No	18		LS2A01	1200	6930	31								
242	L	Adsorption	No			LSAII		20275	247								
252	L	None	No			LM2	2	21900	229								
267	L	EDTA	No			LSAII	700	14330	177								
268	C+L	EDTA	No	18		LS2A01	2000	11401	13	LS2PRA	2000	10013	74				
273	L					LS2A01	1500	11621	73								
277	L	EDTA	No	19		LS2A01	500	7639	31								
284	L	EDTA	No			LS2A01	1000	10193	69.23								
292	L	EDTA	No	18		LS2A01	500	8168	85	LSM12	2.5	11487	47				
293	L	None	No			LS2A01	500	6299	17.6								
294	L	None	No			LSAII		13814									
302	L																
303	L	EDTA, Heat Inactivation	No	16		LS2A01	1000	9453	73								
309	L	None	No			LSAII	500	16300	102								
351	L	EDTA	No	18		LS2A01	1500	9715	62								
361	L	None	No	3006101		LSAII	500	17564	100								
392	L																

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

NEQ-120

Issue 3

UK NEQAS for H+I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 28 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H+I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/201:
DESPATCHED ON 17TH APRIL 2016

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

HLA specificity for assessment																														
Lab no.	DR1 Absent 2.7%			DR103 Absent 1.4%			DR15 Absent 2.7%			DR16 Absent 1.4%			DR17 Not Assessed 26.0%			DR18 Absent 2.7%			DR12 Present 89.0%			DR13 Absent 1.4%			DR7 Present 94.5%			DR9 Present 93.2%		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9																														
11																														
12																														
14																														
15																														
19																														
20																														
23																														
24																														
25																														
26																														
28																														
34																														
35																														
38																														
39																														
41																														
42																														
45																														
48																														
51																														
54																														
58																														
62																														
100																														
112																														
114																														
116																														
117																														
119																														
120																														
133																														
136																														
142																														
143																														
145																														
149																														
157																														
160																														
162																														
165																														
169																														
181																														
185																														
194																														
195																														
197																														
206																														
212																														
214																														
216																														
218																														
222																														
227																														
229																														
230																														
232																														
242																														
252																														
267																														
268																														
273																														
277																														
284																														
292																														
293																														
294																														
302																														
303																														
309																														
351																														
361																														
392																														

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	2 < 2000	1 < 2000	2 < 2000	1 < 2000	19 < 2000	2 < 2000	65 < 2000	1 < 2000	69 < 2000	68 < 2000
Total Participants	73	73	73	73	73	73	73	73	73	73
	1	0	0	0	16	1	16	0	0	0
	2000-5000	2000-5000	2000-5000	2000-5000	2000-5000	2000-5000	2000-5000	2000-5000	2000-5000	2000-5000
	1	0	2	1	2	1	45	0	1	19
	> 5000	> 5000	> 5000	> 5000	> 5000	> 5000	> 5000	> 5000	> 5000	> 5000
	0	0	0	0	0	0	3	0	67	48

NEQ-120

Issue 3

UK NEQAS for H+I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 29 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H+I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

DPB1* Antibodies - ASSESSED																						
Lab no.	01:01 Absent 1.4%			03:01 Absent 1.4%			05:01 Absent 1.4%			13:01 Absent 1.4%			14:01 Absent 1.4%			18:01 Absent 2.7%			28:01 Absent 1.4%			
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	
9																						
11																						
12																						
14																						
15																						
19																						
20																						
23																						
24	01:01	L	2000-5000																			
25																						
26																						
28																						
34																						
35																						
36																						
39																						
41																	18:01	L	< 2000	28:01	L	< 2000
42																						
45																						
48																						
51																						
54																						
58																						
62																						
100																						
112																						
114																						
116																						
117																						
119																						
120																						
133																						
136																						
142																						
143																						
145																						
149																						
157																						
160																						
162																						
165																						
169																						
181																						
185																						
194																						
195																						
197																						
206																						
212				03:01	L	2000-5000																
214																						
216																						
218																						
222																						
227																						
229																						
230																						
232																						
242																						
252																						
267																						
268																						
273																						
277																						
284																						
292																						
293																						
294																						
302																						
303																						
309																						
351																						
361																						
392																						

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	1	< 2000	1	< 2000	1	< 2000	1	< 2000	1	< 2000	2	< 2000	1	< 2000
Total Participants	73	0	73	0	73	0	73	0	73	0	73	1	73	1
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
	1		1		0		0		0		0		0	
	> 5000		> 5000		> 5000		> 5000		> 5000		> 5000		> 5000	
	0		0		0		0		0		0		0	

NEQ-120

Issue 3

UK NEQAS for H+I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 31 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H+I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2011

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	01:01 Absent 1.4%			02:01 Not Assessed 8.2%			03:01 Absent 4.1%			04:01 Absent 4.1%			05:01 Not Assessed 20.5%		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9															
11															
12															
14															
15													05:01	L	> 5000
19															
20	01:01	L	< 2000												
23															
24															
25															
26															
28															
34															
35				02:01	L	2000-5000	03:01	L	2000-5000	04:01	L	2000-5000	05:01	L	2000-5000
38															
39													05:01	L	2000-5000
41															
42															
45															
48															
51															
54															
58															
62															
100															
112															
114															
116															
117													05:01	L	2000-5000
119															
120															
133															
136													05:01	L	> 5000
142													05:01	L	> 5000
143															
145															
149															
157													05:01	L	> 5000
160													05:01	L	2000-5000
162															
165															
169													05:01	L	> 5000
181															
185				02:01	L	< 2000									
194															
195															
197															
206															
212															
214															
216															
218															
222															
227															
229															
230															
232				02:01	L	< 2000	03:01	L	< 2000	04:01	L	< 2000	05:01	L	2000-5000
242															
252				02:01	L	< 2000									
267															
268															
273													05:01	L	> 5000
277													05:01	L	2000-5000
284															
292													05:01	L	> 5000
293															
294															
302															
303													05:01	L	> 5000
309				02:01	L	< 2000									
351				02:01	L	2000-5000	03:01	L	2000-5000	04:01	L	2000-5000	05:01	L	> 5000
361															
392															

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

No. Reporting Spec	1	< 2000	6	< 2000	3	< 2000	3	< 2000	15	< 2000
Total Participants	73	1	73	4	73	1	73	1	73	0
		2000-5000		2000-5000		2000-5000		2000-5000		2000-5000
		0		2		2		2		6
		> 5000		> 5000		> 5000		> 5000		> 5000
		0		0		0		0		9

NEQ-120

Issue 3

UK NEQAS for H+I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 32 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H+I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

DPA1* Antibodies - NOT ASSESSED

Consensus % reported	Lab no.	
9		No Specificities found
11		No Specificities found
12		No Specificities found
14		No Specificities found
15		No Specificities found
19		No Specificities found
20		No Specificities found
23		No Specificities found
24		No Specificities found
25		No Specificities found
26		No Specificities found
28		No Specificities found
34		No Specificities found
35		No Specificities found
38		No Specificities found
39		No Specificities found
41		No Specificities found
42		No Specificities found
45		No Specificities found
48		No Specificities found
51		No Specificities found
54		No Specificities found
58		No Specificities found
62		No Specificities found
100		No Specificities found
112		No Specificities found
114		No Specificities found
116		No Specificities found
117		No Specificities found
119		No Specificities found
120		No Specificities found
133		No Specificities found
136		No Specificities found
142		No Specificities found
143		No Specificities found
145		No Specificities found
149		No Specificities found
157		No Specificities found
160		No Specificities found
162		No Specificities found
165		No Specificities found
169		No Specificities found
181		No Specificities found
185		No Specificities found
194		No Specificities found
195		No Specificities found
197		No Specificities found
206		No Specificities found
212		No Specificities found
214		No Specificities found
216		No Specificities found
218		No Specificities found
222		No Specificities found
227		No Specificities found
229		No Specificities found
230		No Specificities found
232		No Specificities found
242		No Specificities found
252		No Specificities found
267		No Specificities found
268		No Specificities found
273		No Specificities found
277		No Specificities found
284		No Specificities found
292		No Specificities found
293		No Specificities found
294		No Specificities found
302		No Specificities found
303		No Specificities found
309		No Specificities found
351		No Specificities found
361		No Specificities found
392		No Specificities found

Technique : C = CDC; E = ELISA; F = Flow cytometry

No. Reporting Spec
Total Participants

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 33 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 305/2018

DESPATCHED ON 17TH APRIL 2018

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

Lab no.	Techniques used IgG	Sample Treatment IgG	High Background	Neg control serum batch	Allele Specific Antibodies IgG	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot) IgG	Cut-off value IgG	Control bead MFI Positive	Control bead MFI Negative
9	L	EDTA				LSAII	1000	9500	60								
11	L	EDTA	No	18	DRB3*01:01, 03:01	LS2A01	1000	4516	34	LSM12	2.5	6197	60				
12	L	EDTA		18	DRB3*01:01, 03:01	LS2A01	500	10056	29								
14	L	EDTA, Heat Inactivation	No	18	DQB1*05:01	LS2A01	1500	12867	31								
15	L	EDTA	No	18	DRB3*01:01, 03:01	LS2A01	1000	8737	51								
19	L	None	No		DRB3*01:01, 03:01	LS2A01	1000	9334	52								
20	C+L	EDTA	No		DRB3*01:01, 03:01	LS2A01	1000	8954	103								
23	L	EDTA	No	19	DQB1*05:01	LS2A01	1000	10264	15								
24	L	EDTA	No	18		LS2A01	1000	10521	64	LSM12	4.5	10425	249	LS2PRA	1000	11667	85
25	L	EDTA	No	19	DRB3*01:01, 03:01	LS2A01	1000	9164	71	LSM12	6.1	1583	33	LSAII	1500	15418	106
26	L	EDTA	No	19	DRB3*01:01, 03:01	LS2A01	1248	8559	99	LSM12	4.5	12168	159				
28	L	None	No			LS2A01	500	4126	21								
34	L	None	No	18	DRB3*01:01, 03:01	LS2A01	2116/860	12100	41								
35	L	EDTA	No	19		LS2A01	1000	11625	47								
38	L	EDTA	No	18	DRB3*01:01, 03:01	LS2A01	1000	9679	26	LSAII		15840	275				
39	L	EDTA	No	18	DRB3*01:01, 03:01	LS2A01	720	7792	144								
41	L	None	No		DRB3*01:01, 03:01	LS2A01	2000	7377	12								
42	L	EDTA	No	18	DRB3*01:01, 03:01	LS2A01	5800	11043	46								
45	L	EDTA, Adsorption	No		DQB1*05:01	LS2A01	1500	13000	60								
48	L	Heat Inactivation	No	19	DRB3*01:01, 03:01	LS2A01	1600	11069	130								
51	L	EDTA	No	18	DRB3*01:01, 03:01	LS2A01	1000	8089	56								
54	L	EDTA	No	18	DRB3*01:01, 03:01	LS2A01	1000	10752	27								
58	L	None	No	19	DRB3*01:01, 03:01	LS2A01	>1500	10980	31	LSAII	750	14654	205				
62	L	None	No			LSAII	562	14924	19								
100	L	None	No	3006101		LSAII	500	16227	155								
112	L	None	No	3005857		LSAII	500	5376	18								
114	L	EDTA	No			LS2A01	1000	5376	18								
116	L	EDTA	No	18	DRB3*01:01, 03:01	LS2A01	1000	6256	26	LSM12		7174	115				
117	L	None	No	18		LS2A01	500	10307	10								
119	L	EDTA	No	17	DQB1*05:01	LS2A01	>1000	9839	22	LSM12	>1.5	12245	44				
120	L	EDTA	No		DRB3*01:01, 03:01	LS2A01	500	7940	15								
133	L	Heat Inactivation	No	3005855	DRB1*07:01/09:01/12:01	LSAII		16298	114								
136	L	None	No		DRB3*01:01, 03:01	LS2A01	1000	16159	30								
142	L	EDTA	No		DQB1*05:01	LS2A01	1000	10097	25								
143	L	None	No			LS2A01	1000	23492	184								
145	L	None	No	16	DRB3*01:01, 03:01	LS2A01	1000	9872	19								
149	L	None	No		DRB3*01:01, 03:01	LSAII	1000	18546	205								
157	L	EDTA	No	18	DRB3*01:01, 03:01	LS2A01	1000	8587	31.35								
160	L	Adsorption	No	17	DRB3*01:01, 03:01	LS2A01	1000	6391	12.8								
162	L	EDTA	No		DRB3*01:01, 03:01	LS2A01	1000	11274	30	LSM12	3	8125	42				
165	L	None	No			LS2A01	309	7387	23								
169	L	None	No		DQB1*05:01	LS2A01	1000	4824	17								
181	L	None	No	18	DRB3*01:01, 03:01	LS2A01	500	8105	50								
185	L	Heat Inactivation	No		DRB3*01:01, 03:01	LSAII	1907	1907	204	LM2	2	19967	151	LMX	1	18823	128
194	L	EDTA	No		DRB3*01:01, 03:01	LS2A01	1000	10846	18								
195	L	None	No			LS2A01	1000	8590	83								
197	L	None	No			LS2A01	1000	9785	16								
206	L	EDTA	No			LM2		17877	126								
212	L	None	No		DQB1*02:01/02	LSAII	750	15633	336								
214	L	None	No		DRB1*07:01/09:01/12:01/12:02												
216	L	None	No		DRB3*01:01/03:01	LM2	2000	16799	148								
218	L	None	No		DRB1*07:01/09:01	LSAII	750	17223	148								
222	F	None	No		DRB3*01:01/03:01												
227	L	Dilution, EDTA	No														
229	L	None	No	3005989		LM2	1000	>10000	155								
230	L	None	No	18		LS2A01	1200	6503	12								
232	L	Adsorption	No			LSAII	20361	20361	217								
242	L	None	No			LM2	2	22203	139								
252	L	EDTA	No			LSAII	700	13352	116								
267	C+L	EDTA	No	18		LS2A01	2000	9015	11	LS2PRA	2000	8253	58				
268	L	None	No		DRB3*01:01, 03:01	LS2A01	1500	10060	37								
273	L	EDTA	No	19	DRB3*01:01, 03:01	LS2A01	500	7003	22								
277	L	None	No		DQB1*05:01												
284	L	EDTA	No		DRB3*01:01, 03:01	LS2A01	1000	9346	30.25								
292	L	EDTA	No	18	DQB1*05:01	LS2A01	500	9511	67	LSM12	2.5	10713	38				
293	L	None	No		DRB3*01:01/06:01/06:03/06:09												
294	L	None	No		DRB3*01:01, 03:01	LS2A01	500	6580	12.4								
302	L	None	No			LSAII		14933									
303	L	EDTA, Heat Inactivation	No	18	DRB1*15:02	LS2A01	1000	9714	57								
309	L	None	No			LSAII	550	16300	156								
351	L	EDTA	No	18		LS2A01	1500	9007	52								
361	L	None	No	3006101	DRB3*01:01, 03:01	LSAII	500	17867	88								
392	L	None	No														

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

NEQ-120

Issue 3

UK NEQAS for H&I is provided from the Welsh Blood Service, a division of Velindre NHS Trust

P 34 of 34

© Confidential report; no data may be published without permission from UK NEQAS for H&I

Effective Date 13/03/17